PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST
PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST
复制标题
DOI：
10.1016/s0140-6736(87)92208-2
复制
发表时间：
1987-06-27
期刊：
影响因子：
168.9
通讯作者：
COOMBES, RC
中科院分区：
文献类型：
--
作者：
CUNNINGHAM, D;POPLE, A;COOMBES, RC
15例接受细胞毒性药物（除顺铂外）治疗的患者先前发生恶心和呕吐，对一线止吐药难治，在化疗前立即给予选择性5- ht3受体拮抗剂（GR38032F），静脉注射4mg，口服4mg， 5和10小时后重复口服剂量。在24小时内记录恶心、呕吐和副作用。15例患者共接受31个疗程的化疗。仅有1例患者呕吐。唯一的不良事件是1例患者口腔干燥，1例患者轻度镇静，1例患者腹泻，这些不良事件与药物无关。
15 patients receiving cytotoxic drugs (other than cisplatin) that had previously produced nausea and vomiting refractory to first-line antiemetics were given a selective 5-HT3 receptor antagonist (GR38032F), 4 mg intravenously and 4 mg orally, immediately before chemotherapy, the oral dose being repeated 5 and 10 h later. Nausea, vomiting, and side-effects were recorded for the ensuring 24 h. The 15 patients received a total of thirty-one courses of chemotherapy. Only 1 patient vomited. The only adverse events were dryness of the mouth in 1 patient, mild sedation in 1, and diarrhoea in 1, and these were not clearly drug related.